Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANALYSIS: Myriad, Mayo fuel US biotech patent rejections

This article was originally published in Clinica

Executive Summary

Rejections by the US Patent and Trademark Office (US PTO) of applications for biotechnology-related inventions appear to significantly be on the rise after new examination guidelines were put in place following the Supreme Court's rulings in Association for Molecular Pathology v Myriad Genetics and Mayo Collaborative Services v Prometheus Laboratories – two decisions that sent shockwaves through the industry – according to a new report.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel